NCT00525902

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

An Open-label, Multicenter, Phase II Trial of Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Conditions

• Uveitis

Interventions

Type	Name	Description
DRUG	Adalimumab	40 mg delivered every 2 weeks by subcutaneous injection

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2007-09-06
• Last updated: 2012-04-11
• Results posted: 2012-04-09

Locations

1 site across 1 country: United States